@misc{oai:repo.qst.go.jp:00067792,
 author = {Fukuda, Satoshi and Iida, Haruzo and Yan, Xueming and Xie, Yuyuan and 福田 俊 and 飯田 治三 and 厳 雪銘},
 month = {May},
 note = {The effects of long-term administration of Zn-DTPA (diethyene-triamine-penta-actic acid) and CBMIDA [Catechol-3,6-bis(methyleiminodiaetic acid)] on plutonium-induced bone tumors and shortening of life span in rats were examined. One-hundred-twenty female rats were injected with doses of 18.5, 37, and 370 kBq/kg of plutonium-239. A daily intrperitoneally injected dose of 30 mmol/kg Ca-DTPA was administered to each of 40 rats of the 18.5, 37, and 370 kBq/kg of plutonium groups for first three days followed by the same dose of Zn-DTPA in orally administered in dinking water, while another 40 rats injected with 37 kBq/kg of plutonium were injected intraperitoneally with 30 mmol/kg CBMIDA for the first three days followed by oral administration. High urinary excretion of plutonium was observed for 14-21 days after plutonium injection in the chelating agent-treated groups. In the Zn-DTPA and CBMIDA treated groups, the mean life spans were significantly more prolonged compared with each corresponding (plutonium-injected) group. The incidences of bone tumors in the Zn-DTPA groups were reduced to zero from 10% in the 18.5 and 37 kBq/kg plutonium groups, while they increased to 10% from zero in the 370 kBq/kg plutonium group. The results indicated that human doses of Zn-DTPA and CBMIDA were effective in reducing plutonium-induced effects such as the shortening of life span and the induction of bone tumors in rats., 11th International Congress of the International Radiation Protection Association},
 title = {A long-term treatment of chelating agents, Zn-DTPA and CBMIDA,reduces cancers and prevents shortening of life span in plutonium administered rats},
 year = {2004}
}